Browse the evidence

Tirzepatide (0.144 mg/kg) significantly reduces voluntary alcohol consumption, prevents binge-like drinking, and suppresses relapse-like behaviors in rodents.

Tirzepatide, a dual GLP-1/GIP agonist, significantly reduces alcohol consumption and prevents relapse in rodent models by attenuating dopamine reward signaling. While preclinical, these findings suggest potential for treating Alcohol Use Disorder (AUD) and its metabolic complications.

Administration of BHB-Phe (50 mg/kg, IP) suppresses food intake and body weight in obese mice by activating distinct hypothalamic and brainstem neural populations, independent of melanocortin, GLP-1, or GDF15 pathways.

This research identifies a specific metabolite, BHB-Phe, which reduces food intake in obese mice. It works by activating specific brain regions, distinct from other known weight loss pathways. While the pathway is conserved in humans, direct efficacy in humans has not been established. Current BHB supplements do not necessarily provide this specific conjugate in bioavailable forms or doses shown to be effective in mice.

SGLT2 inhibitors reduce the risk of developing diabetes in high-risk patients with heart failure or chronic kidney disease.

If you have heart failure or kidney disease, even without diabetes, ask your doctor if an SGLT2 inhibitor is right for you. These drugs protect your heart and kidneys and may also prevent diabetes.

GLP-1 receptor agonists (Semaglutide, Tirzepatide) activate human hypothalamic POMC neurons via L-type calcium channels, causing sustained membrane depolarization and increased action potential firing.

GLP-1 drugs like Semaglutide work by directly activating specific neurons in your brain (POMC neurons) that suppress appetite. This activation is sustained and mediated by calcium channels, suggesting the brain plays a central role in the weight loss effects, not just stomach emptying.

Tirzepatide increases the risk of total adverse events (TAEs) and adverse events leading to discontinuation (DAEs) in a dose-dependent manner, with the 15mg dose having the highest risk.

Tirzepatide (TZP) comes with a higher risk of side effects, especially at the 15mg dose. These side effects, which often include gastrointestinal issues like nausea and vomiting, can lead to patients stopping the medication. The risk of these side effects increases with the dose. Patients with obesity may experience more side effects than those with T2DM. It is important to discuss these potential side effects with your doctor and monitor how your body responds to the medication.

Tirzepatide (5, 10, and 15 mg weekly) improves metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis.

If you have moderate to severe fatty liver disease (MASH) with scarring (fibrosis), tirzepatide (5-15 mg weekly) can help resolve the liver inflammation and scarring in about 62% of patients at the highest dose, without making the scarring worse.

Leptin resistance is a common trait in obesity that impairs the feedback between fat mass and the hypothalamus, leading to dysregulated appetite and energy storage.

In obesity, the hormone leptin, which signals satiety, often stops working effectively (leptin resistance). This means the brain doesn't receive the 'stop eating' signal even when fat stores are high, contributing to continued overeating.

Short-term intensive insulin therapy (SIIT) using continuous subcutaneous insulin infusion or multiple daily injections for 2-3 weeks can induce sustained drug-free remission in newly diagnosed type 2 diabetes patients by restoring beta-cell function and reducing glucotoxicity.

If you were recently diagnosed with high blood sugar, ask your doctor about a short course of intensive insulin therapy (2-3 weeks). This 'reset' can restore your body's ability to manage blood sugar on its own, potentially allowing you to avoid lifelong medication.

Tirzepatide exposure does not significantly increase or decrease the risk of adverse cardiovascular events (myocardial infarction, coronary artery disease, heart failure, stroke) or adverse renal events (urinary tract infections, kidney stones, renal impairment, renal cell carcinoma) in participants with type 2 diabetes or obesity compared to control groups.

For patients with T2DM or obesity, current evidence from multiple randomized trials indicates that tirzepatide does not significantly increase or decrease the risk of major cardiovascular events (like heart attack or stroke) or specific renal adverse events (like kidney stones or UTIs) compared to other treatments or placebo. While long-term safety in high-risk groups requires more data, short-to-medium term use appears safe regarding these specific outcomes.

GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide reduce adipocyte size and promote the browning of white adipose tissue (WAT) by upregulating thermogenic genes (e.g., UCP1) and activating the AMPK/SIRT1 pathway, thereby shifting adipose tissue function from energy storage to energy expenditure.

If you are taking a GLP-1 medication like semaglutide or liraglutide, understand that it is actively remodeling your fat tissue. It shrinks fat cells and activates 'browning' processes that burn energy, which is a key part of why these drugs are effective for long-term metabolic health, beyond just reducing your appetite.

Combining tirzepatide with leptin produces synergistic weight loss and improved metabolic homeostasis in diet-induced obesity models, driven by reduced food intake and increased energy expenditure.

For individuals with obesity who have leptin resistance, adding leptin to tirzepatide treatment may enhance weight loss and metabolic health beyond what tirzepatide achieves alone. This synergy works by reducing food intake and increasing energy expenditure, suggesting that combination therapies targeting multiple hormonal pathways can overcome resistance mechanisms.

GLP-1 receptor agonist therapy is associated with significant gastrointestinal adverse events and weight regain upon discontinuation, limiting its long-term durability compared to surgery.

GLP-1 medications like semaglutide or liraglutide can help you lose 15-25% of your body weight, but you may experience nausea, vomiting, or digestive issues. Crucially, if you stop taking the medication, you are likely to regain the weight. Surgery offers more sustained weight loss and cardiovascular protection, though it involves surgical risks.

Resmetirom (THR-β agonist) improves biopsy-confirmed MASH resolution and fibrosis without causing significant weight loss, acting through a lipid-centric mechanism.

If you have MASH, resmetirom is a daily pill that targets liver fat and inflammation directly. It works even if you don't lose weight, making it a distinct option from weight-loss drugs.

A unimolecular antibody-peptide conjugate combining GIP receptor antagonism and GLP-1 receptor agonism (AMG 133) produces significant, sustained body weight loss in obese non-human primates when administered via once-weekly subcutaneous injection.

This research identifies AMG 133 as a potent obesity treatment in primates, achieving nearly 17% body weight loss with once-weekly injections. For humans, this suggests a future therapy that is more convenient than daily injections and potentially better tolerated than current single-target GLP-1 drugs, though it is not yet available for clinical use.

Retatrutide, a triple incretin agonist, alleviates adipose tissue fibrosis and dysfunction by reprogramming lipid metabolism and suppressing inflammatory pathways, rather than solely reducing fat mass.

Retatrutide is a potent injectable medication for obesity that works by fundamentally changing how fat tissue functions—reducing inflammation and fibrosis and improving metabolic health—rather than just suppressing appetite. It requires regular injections (every 3 days) and is most effective for individuals with significant diet-induced metabolic dysfunction.

In Heart Failure with Reduced Ejection Fraction (HFrEF), NuSH therapies show promise in reducing cardiovascular mortality and MACE, but require cautious patient selection and monitoring due to potential chronotropic effects (increased heart rate) and arrhythmia risks observed with earlier generation agents.

For heart failure with reduced ejection fraction (HFrEF), NuSH therapies are not yet a standard first-line treatment due to safety concerns like increased heart rate. However, recent real-world data suggests they may significantly reduce mortality in stable patients. If your doctor considers this, ensure you are clinically stable, have a normal resting heart rate, and are monitored closely. It is crucial to combine this therapy with resistance training and high protein intake to prevent muscle loss, which can be a side effect of rapid weight loss.

Specific gut microbial metabolites (SCFAs, Bile Acids, Tryptophan derivatives) stimulate GLP-1 secretion from intestinal L cells via specific receptors (FFAR2/3, TGR5, GPR142).

Consuming fiber (for SCFAs), specific fermented foods (for BAs), and tryptophan-rich foods can naturally boost GLP-1 by activating specific gut receptors. This supports metabolic and musculoskeletal health.

GLP-1 receptor agonists exert tissue-protective effects across multiple organs (pancreas, heart, liver, adipose, muscle, kidney, brain) primarily by driving mitochondrial remodeling, including improved biogenesis, quality control, and reduced oxidative stress.

GLP-1 medications (like semaglutide or liraglutide) do more than just help you lose weight; they actively improve the energy-producing centers (mitochondria) in your heart, liver, and other organs. This cellular repair helps protect these organs from damage, offering benefits that go beyond simple calorie reduction.

In pancreatic beta cells, GLP-1 receptor agonists directly protect against apoptosis and improve insulin secretion by enhancing mitochondrial ATP production, reducing oxidative stress, and promoting autophagy.

For people with Type 2 Diabetes, GLP-1 drugs help preserve the insulin-producing cells in the pancreas by keeping their energy factories (mitochondria) healthy and reducing cellular stress. This helps maintain the body's natural ability to produce insulin.

Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice.

Practitioners should stay informed about new pharmacological options for obesity management.

GLP-1 receptor agonists exert direct antihypertensive effects independent of weight loss by modulating the sympathetic nervous system, improving endothelial function, enhancing renal sodium excretion, and suppressing the renin-angiotensin-aldosterone system.

Even without losing weight, GLP-1 medications help lower blood pressure by directly relaxing blood vessels, helping your kidneys excrete more sodium, and calming the nervous system signals that raise blood pressure. They also reduce the activity of hormones that constrict blood vessels.

Semaglutide likely results in little to no difference in quality of life with a mean difference of 2.12 (95% CI 0.95 to 3.28) in SF-36 physical functioning score at medium-term follow-up.

While semaglutide aids in weight loss, its impact on quality of life may be minimal.

Tirzepatide is under evaluation for treatment of non-alcoholic steatohepatitis, heart failure, and obstructive sleep apnea.

Practitioners should consider Tirzepatide's potential for treating these additional conditions in future practice.

Adverse events (AEs) were more common in the T2D group (78.3% vs. 50.0%).

Healthcare providers should monitor for gastrointestinal symptoms in T2D patients using tirzepatide.